Strategic partnership with JW Therapeutics to accelerate development of cell therapies targeted to solid tumors Abecma generated $ 75M U.S. commercial revenue in 3Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Ended quarter with $324.5M cash, cash equivalents, and
Data from KarMMa-2 Cohorts 2a and 2c suggest potential for early treatment with Abecma in patients with second-line and newly diagnosed multiple myeloma Data suggest promising outcomes can be achieved treating patients with suboptimal response after transplant Results support further evaluation of
Initial focus on accelerating development of 2seventy bio’s MAGE-A4 program in solid tumors in China CAMBRIDGE, Mass. & SHANGHAI --(BUSINESS WIRE)--Oct. 27, 2022-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and
This study will evaluate Abecma in patients with suboptimal response to transplant Data from KarMMa-3 and KarMMa-2 studies of Abecma will be presented at future medical meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 7, 2022-- 2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 31, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in the following upcoming investor conferences: 17th Annual Citi BioPharma Conference , “Cell
ABECMA generated $ 72M U.S. commercial revenue in 2Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Results from prespecified interim analysis of KarMMa-3 trial shows ABECMA (idecabtagene vicleucel) significantly improves progression-free survival versus standard
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference , “A View to a Kill(er Cell) – Part 1” panel on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 3:20pm PT .
First patients enrolled in clinical studies in bNHL and AML ABECMA generated $56M U.S. commercial revenue in 1Q; continues to track toward upper end of $250-$300M U.S. ABECMA revenue guidance for 2022 Ended quarter with $452.5M cash, cash equivalents, and marketable securities; anticipated cash
